Humacyte, Inc. — Director's Dealing 2022

Dec 20, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2022-12-16

Reporting Person: Dougan Brady W (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-16	Common Stock	S	239538	$2.53	Disposed	17990736	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	510161	Direct
Common Stock	1160240	Indirect

Footnotes

F1: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer.

F2: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.50 to $2.63. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.